Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome
Dolores Subirá(Hospital Universitario de Guadalajara), Dunia de Miguel(Hospital Universitario de Guadalajara), Uta Oelschlaegel(University Hospital Carl Gustav Carus), Theresia M. Westers(Vrije Universiteit Amsterdam), Anna Porwit(Lund University), Nuria Golbano(Hospital Universitario de Guadalajara), Canan Alhan(Vrije Universiteit Amsterdam), Arjan A. van de Loosdrecht(Dutch Cancer Society), Lars Nilsson(Skåne University Hospital), Katherina Psarra(Evangelismos Hospital)
Cited by 7
Related Papers
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714